Spray dried lipid nanoparticle formulations enable intratracheal delivery of mRNA

RNA therapies have recently taken a giant leap forward with the approval of OnpattroTM, a siRNA therapy delivered using a lipid nanoparticle (LNP), and the LNP-enabled mRNA vaccines against COVID-19, which are the first mRNA drugs to reach the marketplace. The latter medicines have illustrated that stability is a significant challenge in the distribution of RNA drugs using non-viral delivery systems, particularly in areas without cold chain storage. Here, we describe a proof-of-concept study on the engineering of an LNP mRNA formulation suitable for spray drying. This process produced a dry powder formulation that maintained stability and preserved mRNA functionality with increased performance compared to liquid formulations stored two weeks at 4 degrees C. Intratracheal delivery of spray dried LNPs loaded with eGFP mRNA to rats resulted in the production of the eGFP protein in a range of cell types including bronchiolar epithelial cells, macrophages and type II pneumocytes; cell types involved in adaptive immunity and which would be valuable targets for inhaled vaccines against respiratory pathogens. Together, these data show that spray drying of LNPs enhances their stability and may enable RNA delivery to the lung for protein replacement therapy, gene editing, vaccination, and beyond.

Automated summary

RNA therapies have advanced significantly with the development of lipid nanoparticle (LNP) delivery and spray-dried LNP mRNA formulations, which enhance stability and enable targeted delivery to the lung. These innovations have wide-ranging applications in protein replacement therapy, gene editing, vaccination, and more.